ERYTECH Pharma develops innovative cancer therapies that work by starving tumors.
Its first product reported positive Phase III results of its pivotal study in Acute Lymphoblastic Leukemia (ALL) in Europe and is in four other clinical programs : a Phase IIb study in Acute Myeloid Leukemia (AML) , a Phase II study in pancreas cancer and an Expanded Access program in ALL in Europe, and a Phase I/II study in ALL in the USA.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyon with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements, one with Orphan Europe (Recordati) and one with TEVA.
ERYTECH Pharma announces a positive DSMB safety review following the treatment of the first twenty-four patients with ERY-ASP in its Phase 2 study in pancreatic cancer
ERYTECH Inc., the US affiliate of ERYTECH Pharma announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs
ERYTECH Pharma reports cash balance and revenues for the second quarter of 2015
ERYTECH Pharma announces positive safety reviews after the completion of the first cohort in the company’s US Phase I study with ERY-ASP in Acute Lymphoblastic Leukemia (ALL), and following the treatment of the first three patients with ERY-ASP in combination with Folfox in its Phase II study in pancreatic cancer.
ERYTECH Pharma attends BIO 2015 in Philadelphia, PA, USA from June 15 to 18, 2015.
ERYTECH Pharma participates and presents at EHA 20th Congress which takes place from June 11 to 14, 2015 in Vienna, Austria.
ERYTECH PHARMA attends and presents at Jefferies 2015 Healthcare Conference from June 1 to 4, 2015 in New-York, NY, USA
ERYTECH participates in 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) which takes place in Chicago, Il, USA from May 29 to June 2, 2015 and makes a poster and an oral presentation